Pulse Biosciences, Inc. Share Price

Equities

PLSE

US74587B1017

Advanced Medical Equipment & Technology

Market Closed - Nasdaq 21:00:00 26/04/2024 BST 5-day change 1st Jan Change
7.19 USD +7.47% Intraday chart for Pulse Biosciences, Inc. 0.00% -41.26%
Sales 2021 1.42 113.13 Sales 2022 0.7 55.85 Capitalization 103M 8.23B
Net income 2021 -63M -5.03B Net income 2022 -58M -4.63B EV / Sales 2021 297,232,229 x
Net cash position 2021 17.36M 1.39B Net Debt 2022 14.82M 1.18B EV / Sales 2022 168,485,877 x
P/E ratio 2021
-6.51 x
P/E ratio 2022
-1.61 x
Employees 61
Yield 2021 *
-
Yield 2022
-
Free-Float 29.62%
More Fundamentals * Assessed data
Dynamic Chart
1 day+7.47%
Current month-17.45%
1 month-17.45%
3 months-15.61%
6 months+72.42%
Current year-41.26%
More quotes
1 week
6.60
Extreme 6.595
7.21
1 month
6.60
Extreme 6.595
8.34
Current year
6.60
Extreme 6.595
12.22
1 year
3.78
Extreme 3.78
13.62
3 years
1.18
Extreme 1.18
29.16
5 years
1.18
Extreme 1.18
45.82
10 years
1.18
Extreme 1.18
45.82
More quotes
Managers TitleAgeSince
Chief Executive Officer 54 13/02/22
Chief Tech/Sci/R&D Officer - 02/05/23
Chief Tech/Sci/R&D Officer - -
Members of the board TitleAgeSince
Chairman 79 01/11/17
Director/Board Member 46 01/11/17
Chief Tech/Sci/R&D Officer 59 14/09/15
More insiders
Date Price Change Volume
26/04/24 7.19 +7.47% 71,325
25/04/24 6.69 -2.48% 117,307
24/04/24 6.86 0.00% 129,156
23/04/24 6.86 +0.15% 124,448
22/04/24 6.85 -4.73% 94,131

Delayed Quote Nasdaq, April 26, 2024 at 09:00 pm

More quotes
Pulse Biosciences, Inc. is a bioelectric medicine company. The Company’s proprietary CellFX nsPFA technology delivers nanosecond pulses of electrical energy to non-thermally clear cells while sparing adjacent noncellular tissue. The Company is engaged in the development of its CellFX nsPFA technology for use in the treatment of atrial fibrillation and in a select few other markets where it could have a profound positive impact on healthcare for both patients and providers. The Company’s Nano-pulse Stimulation (NPS) technology is an energy modality that delivers nanosecond-duration pulses of electrical energy, each less than a millionth of a second long, to non-thermally clear targeted cells while sparing adjacent noncellular tissue. The Company has designed a variety of applicators, or end-effectors, to explore the potential use of the CellFX platform to treat disorders in other medical specialties, such as cardiology, gastroenterology, gynecology, and ear, nose, and throat.
Calendar
Related indices
More about the company